Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | March 1, 2018 |
| End Date: | June 1, 2021 |
| Contact: | Robert Lustig, MD |
| Email: | PennCancerTrials@emergingmed.com |
| Phone: | 855-216-0098 |
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation
therapy in patients with glioblastoma, as measured by estimating the median of
progression-free survival. Toxicity, patterns of recurrence, and overall median survival will
be measured as secondary endpoints. Adverse events will be monitored.
therapy in patients with glioblastoma, as measured by estimating the median of
progression-free survival. Toxicity, patterns of recurrence, and overall median survival will
be measured as secondary endpoints. Adverse events will be monitored.
Inclusion Criteria:
- Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total
resection, who are undergoing definitive chemoradiation as part of their treatment
regimen
- Age 18 or older
- Ability to give signed informed consent
- Karnofsky Performance Status (KPS) at least 70
Exclusion Criteria:
- Placement of Gliadel wafers
- Participation in another investigational trial
- Active treatment of another malignancy
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Robert Lustig, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
